Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients Posted bylwm100 October 7, 2021 Leave a comment on Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients https://www.redhillbio.com/news/news-details/2021/RedHill-Biopharma-Reports-Further-Analysis-of-Phase-23-Data-Including-a-62-Reduction-in-Mortality-with-Oral-Opaganib-in-Moderately-Severe-COVID-19-Patients/default.aspx
